menu
    • menu
    [{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"VarmX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Preclinical","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VarmX \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VarmX \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Rallybio Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Rallybio Corporation"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"Blood Stem cell-based Therapy","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Garuda Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Garuda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Garuda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"Ex-vivo NK Cell Therapy","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":1.24,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : RLYB331

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Rallybio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

                            Details : Rallybio plans to prosecute preclinical activities for KY1066/RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.

                            Brand Name : KY1066

                            Molecule Type : Large molecule

                            Upfront Cash : $3.0 million

                            May 10, 2022

                            Lead Product(s) : RLYB331

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Rallybio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prime Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies

                            Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prime Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell-based Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BMS Pays Prime $110M to Form T-cell Therapy Pact

                            Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $110.0 million

                            September 30, 2024

                            Lead Product(s) : T-Cell-based Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Scribe Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Scribe Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ex-vivo NK Cell Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,240.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and...

                            Details : Under the collaboration, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo NK-cell therapies, including sickle cell disease.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $40.0 million

                            July 17, 2023

                            Lead Product(s) : Ex-vivo NK Cell Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,240.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Porton Advanced Solutions

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Engineering

                            Details : This collaboration will accelerate the development of innovative therapeutics for the treatment of some diseases such as blood, skin, and liver-related diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Garuda Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Garuda Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Blood Stem cell-based Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $62.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Fly Like an Eagle: Garuda Brings in A $62M Series B

                            Details : The Series B funds will funnel into two programs Blood stem cell-based therapy, slated to hit the clinic in 2024 - transfusion-dependent beta-thalassemia (TDBT) in Europe and bone marrow failure syndrome in Europe, South America and North America

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 07, 2023

                            Lead Product(s) : Blood Stem cell-based Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $62.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Disc medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Disc medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DISC-0998

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hem...

                            Details : DISC-0998 is an investigational anti-HJV mAb with an engineered Q and L mutation (QL-mutation) in the Fc region, aimed to alter binding to the FcRn receptor, resulting in an increased PK half-life.

                            Brand Name : DISC-0998

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : DISC-0998

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            VarmX

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

                            Details : Company announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001able to rapidly and effectively restore coagulation in the presence of FXa DOAC, the Trial will assess safety, tolerability, PK and PD.

                            Brand Name : VMX-C001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 15, 2021

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CANbridge Pharmaceuticals

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            CANbridge Pharmaceuticals

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAN106

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : WuXi Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Canbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for Complement Dys...

                            Details : CANbridge is developing CAN106, in conjunction with WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, as part of a strategic partnership for the development of rare disease therapeutics.

                            Brand Name : CAN106

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 18, 2020

                            Lead Product(s) : CAN106

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : WuXi Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Progr...

                            Details : The FDA provided feedback for ARCA's clinical development plans for evaluating AB201 as a potential treatment for patients with severe COVID-19.

                            Brand Name : AB201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 12, 2020

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth